Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma

NCT03194867 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03194867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03194867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
February 21, 2018
Completion date
April 5, 2023
Enrollment
109 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma